7:13AM Auxilium Pharma and FCB I LLC announce the issuance of composition of matter patent covering Testim (AUXL) 18.49 : Co and FCB I LLC announced that the United States Patent and Trademark Office has issued U.S. Patent No. 8,178,518 covering, among other things, Testim 1% testosterone gel, marketed by Auxilium under license from FCB. The newly issued patent, which claims certain pharmaceutical compositions comprising testosterone, is expected to expire in April 2023. Auxilium has also submitted the patent for listing in the Approved Drug Products with Therapeutic Equivalence Evaluations, published by the U.S. Food and Drug Administration.